Details der Publikation - A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP)

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP) : A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP)

Medienart:	Klinische Studie

Erscheinungsjahr:	2021
Erschienen:	2021

Enthalten in:	WHO International Clinical Trials Registry Platform - (2021) vom: 13. Sept. Zur Gesamtaufnahme - year:2021

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: COVID-19 MedDRA version: 23.0Level: LLTClassification code 10084382Term: Coronavirus disease 2019System Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02] Phase: Phase 2 Recruitment Status: Authorised-recruitment may be ongoing or finished Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 28-05-2021, Last updated: 2022-11-24

ICTRP ID:	EUCTR2020-006082-11-DE ADG20-TRMT-001 2020-006082-11-GR

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	WHO007781121

Internformat


LEADER	01000caa a22002652 4500
001	WHO007781121
003	DE-627
005	20230425171901.0
007	cr uuu---uuuuu
008	210730s2021 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)WHO007781121
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2020-006082-11-DE
035			\|a (UBBS_Klinische_Studien_WHO)ADG20-TRMT-001
035			\|a (UBBS_Klinische_Studien_WHO)2020-006082-11-GR
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP) \|b A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP)
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 28-05-2021, Last updated: 2022-11-24
650		4	\|a Medical Condition: COVID-19 MedDRA version: 23.0Level: LLTClassification code 10084382Term: Coronavirus disease 2019System Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 2
650		4	\|a Recruitment Status: Authorised-recruitment may be ongoing or finished
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2021) vom: 13. Sept.
773	1	8	\|g year:2021 \|g day:13 \|g month:09
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-006082-11 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2021 \|b 13 \|c 09

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände